Critical differences among beta-adrenoreceptor antagonists in myocardial failure: Debating the MERIT of COMET

Journal of Clinical Pharmacology

Volumn 45, Issue 1, 2005, Pages 6-24

  McBride, Brian F ^a   White, C Michael ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Beta adrenoreceptor antagonists; Carvedilol; Drug interactions; Heart failure; Metoprolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NORADRENALIN; PLACEBO; CARBAZOLE DERIVATIVE; METOPROLOL; PROPANOLAMINE DERIVATIVE;

ADRENERGIC SYSTEM; ADULT; CARDIOVASCULAR DISEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS;

EID: 16644382540     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269841     Document Type: Review

References (109)

1. Beta Blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982;247:1707-1714.
2. Hjalmarson A, Herlitz J, Malek I, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet. 1981;2:823-827.
3. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
4. The Beta Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988;9:8-16.
5. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the management of chronic heart failure in the adult. J Am Coll Cardiol. 2001;38:2101-2113.
6. Stafford RS, Radley DC. The underutilization of medications of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56-61.
7. McCormick D, Gurwitz JH, Lessard D, Yarzebeski J, Gore JM, Goldberg RJ. Use of aspirin beta-blockers, and lipid lowering medications before recurrent myocardial infarction: missed opportunities for prevention? Arch Intern Med. 1999;159:561-567.
8. Mendelson G, Aronow WS. Underutilization of beta blockers in older patients with prior myocardial infarction or coronary artery disease in an academic hospital based geriatrics practice. J Am Ger Soc. 1997;45:1360-1361.
9. Fishkind D, Paris BE, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital based geriatrics practice. J Am Ger Soc. 1997;45:809-812.
10. Howard PA, Shireman TI. Examination of drug therapy patterns and relationship to heart failure hospitalization in Medicaid patients. Am J Manage Care. In press.
11. Gupta W, Tang WHW, Young JB. Patterns of beta blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J. 2004;147:79-83.
12. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
13. Quaife RA, Gilbert EM, Chrisitan PE, et al. Effects of carvedilol on systolic and diastolic performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996;78:779-784.
14. Capomolla S, Febo O, Gnemmi M, et al. Beta blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J. 2000;139:596-608.
15. Cice G, Ferrara L, DiBennedetto A, et al. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a randomized double blind placebo controlled trial. J Am Coll Cardiol. 201;37:407-411.
16. Cleland JGF, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial) randomized controlled trial. Lancet. 2003;362:14-21.
17. Australia-New Zealand Heart Failure Research Collaborative Group. Congestive heart failure: effects of carvedilol, a vasodilator beta blocker in patients with congestive heart failure due to ischemic disease. Circulation. 1995;92:212-218.
18. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECI SE trial. Circulation. 1996;94:2793-2799.
19. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with heart failure. N Engl J Med. 1996;334:1349-1355.
20. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806.
21. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 1997;34;349:375-380.
22. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
23. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA. 2003;289:712-718.
24. Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (A subgroup of the Goteberg Metoprolol Trial). Am J Cardiol. 1997;80:40J-44J.
25. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double blind, randomized, placebo controlled trial. Circulation. 1985;72:536-546.
26. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
27. Goldstein S, Kennedy HL, Hall C, et al. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability safety, and effect on the left ventricular ejection fraction. Am Heart J. 1999;138:1158-1165.
28. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HBW, Hilderbrandt PR. Antiremodeling effects on the left ventricle during beta blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol. 2000;36:2072-2080.
29. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HP). JAMA. 2000;283:1295-1302.
30. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
31. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. J Am Coll Cardiol. 2002;40:491-498.
32. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
33. DiLenarda A, Sabbadini G, Salvatore L, et al. Long term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol. 1999;33:1926-1934.
34. Kukin ML, Kalman J, Charney RH, et al. Prospective randomized comparison of effect of long term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fractions, and oxidative stress in heart failure. Circulation. 1999;25:2645-2651.
35. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet. 2003;362:7-13.
36. Metra M, Poole-Wilson PA, Cleland JG, et al. Beta blocker dose does not influence the beneficial effects of carvedilol compared to metoprolol in patients with heart failure: results from the carvedilol or metoprolol European trial (COMET) [abstract]. J Am Coll Cardiol. 2004;43(suppl A):206A.
37. De Mey C, Breithaupt-Grogler K, Schloos J, Palm D, Belz GG. Reproducibility and consistency of the responses to supine bicycle ergometry: evaluation in conjunction with β-1 adrenoreceptor occupancies. Br J Clin Pharm. 1994;38:480-483.
38. Katz AM. Cellular and molecular basis of myocardial contraction. In: Narula J, Virmani R, Ballester M, et al, eds. Heart Failure: Pathogenesis and Treatment. London: Martin Dunitz; 2002:3-20.
39. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:41-52.
40. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down regulation and subsensitivity to agonist response. Circulation. 1986;74:1290-1302.
41. Abdellatif M, Schneider MD. Transcriptional circuits mediating cardiac hypertrophy and heart failure. In: Narula J, Virmani R, Ballester M, et al, eds. Heart Failure: Pathogenesis and Treatment. London: Martin Dunitz; 2002:59-67.
42. Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am J Cardiol. 1997;80:26L-40L.
43. Rundquist B, Elam M, Bergmann-Sverrisdottir Y, Esenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169-175.
44. Bristow MR, Minobe W, Rasmussen R, et al. β-Adrenergic neuro-effector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
45. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler M. Adverse consequences of high sympathetic nervous system activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
46. Freedman NJ, Liggett SB, Drachmen DE, Pei G, Caron MG, Lefkowitz RJ. Phosphorylation and desensitization of the human β-1 adrenergic receptor. J Biol Chem. 1995;270:17953-17961.
47. 2+-ATPAse gene expression in the human ventricule during end stage heart failure. J Clin Invest. 1990;85:305-309.
48. Bristow MR, Ginsburg R, Umas V, et al. β-1 and β-2 adrenergic receptor suhpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contractions and selective β-1 receptor downregulation in heart failure. Circ Res. 1986;9:297-309.
49. 2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and filing human ventricular myocardium. Mol Pharmacol. 1989;5:295-303.
50. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
51. Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation. 1983;67:1356-1367.
52. Tanabe Y, Inagaki M, Kurita T, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol. 2001;37:911-919.
53. Tran H, White CM, Chow MSS, Kluger J. An evaluation of the impact of gender and age on QT dispersion in healthy volunteers. Ann Noninv Electrocardiol 2001;6:129-133.
54. Kluger J, Giedrimiene D, White CM, Verroneau J, Giedrimas E. A comparison of the QT and QTc dispersion among patients with sustained tachyarrhythmias and different etiologies of heart disease. Ann Noninv Electrocardiol. 2001;6:319-322.
55. Shimuzu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol. 2003;41:633-642.
56. Sun ZH, Swan H, Viitasalo M, Toivonen L. Effects of epinephrine and phenylephrine on QT dispersion in congenital long QT syndrome. J Am Coll Cardiol. 1998;31:1400-1405.
57. Darbar D, Smith M, Morike K, Roden DM. Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. Am J Cardiol. 1996;77:1351-1355.
58. Kathhofer S, Zhang W, Karle C, Thomas D, Schoels W, Kiehn J. Functional coupling of human beta-3 adrenoreceptors to the KvLQT1/MinK potassium channel. J Biol Chem. 2000;275:26743-26747.
59. Peralta EG. Dual modulation of a potassium channel by the m1 muscarinic and beta 2 adrenergic receptors. Life Sci. 1995;56:957-964.
60. McBride BF, Kalus JS, Caron MF, Guertin DC, Kluger J, White CM. The electrocardiographic impact of catecholamines among patients at high risk of ventricular arrhythmogenesis. J Electrocardiol. Submitted for publication.
61. White CM, Chow MSS. Cardiac arrhythmias. In: Koda-Kemble MA, Young LY, eds. Applied Therapeutics: The Clinical Use of Drugs. Philadelphia: Lippincott Williams & Wilkins; 2001;18.1-18.36.
62. Nabauer M, Beuckelmann DJ, Uberfuhr P, Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation. 1996;93:168-177.
63. Narula J. Programmed myocyte death in heart failure. N Engl J Med. 1996;335:1182-1189.
64. Sharov VG, Goussev A, Higgins RSD, et al. Higher incidence of cardiocyte apoptosis in failing explanted hearts of patients with ischemic versus idiopathic dilated cardiomyopathy [abstract]. Circulation. 1997;96:I-17.
65. Matsui T, Hajjar RJ, Kang JX, Rosenzwig A. Norepinephrine directly induces apoptosis in neonatal rat myocytes. J Am Coll Cardiol. 1997;29:230A.
66. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult ventricular myocytes by activation of the beta adrenergic pathway. Circulation. 1998;98:1329-1334.
67. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis if adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859-870.
68. Suenobu N, Shichiri M, Iwashina M, Marumo F, Hirata Y. Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Art Thromb Vasc Biol. 1999;19:141-146.
69. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor α induced apoptosis in cardiac myocytes: involvement of the sphingo-lipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
70. Bristow MR, Abraham WT, Gilbert EM, Yoshikawa T, Port JD. Relationships between carvedilol stereoisomer plasma concentrations and b-receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial [abstract]. Eur Heart J. 1996;17:135.
71. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl I):S68-S80.
72. Yao A, Kohmoto O, Oyama T, et al. Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol. Circulation J. 2003;67:83-90.
73. Heilbrunn SM, Shah P, Bristow MR, Valentine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
74. Bohm M, Ettelbruck S, Flesch M, et al. β-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res. 1998;40:146-155.
75. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104:2194-2199.
76. Richardt G, Richardt D, Adler S, Kraatz E, Notzold A, Kurz T. Unique effects of carvedilol on noradrenaline release in the human heart. Eur J Heart Failure. 2002;4:147-149.
77. Fung JWH, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin angiotensin aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003;92:406-410.
78. Pousset F, Copie X, Lechat P, et al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol. 1996;77:612-617.
79. Mortara A, LaRovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol. 2000;36:1612-1618.
80. Goldsmith RL, Bigger T, Bloomfield DM, et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol. 1997;80:1101-1104.
81. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98:1783-1789.
82. Yue TL, Ma XL, Gu JL, Ruffolo RR, Feuerstein GZ. Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart. Eur J Pharmacol. 1998;345:61-65.
83. 2 adrenoreceptor. J Cardiovasc Pharmacol. 2002;40:448-455.
84. Sung CP, Arleth AJ, Eichman C, Truneh A, Ohlstein EH. Carvedilol, a multiple action neurohormonal antagonist, inhibits mitogen activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther. 1997;283:910-917.
85. Kajiwara K, Yanagita T, Nakashima Y, Wada A, Izumi F, Yanagihara N. Differential effects of short and prolonged exposure to carvedilol on voltage dependent Na+ channels in cultured bovine adrenal medullary cells. J Pharmacol Exp Ther. 2002;32:212-218.
86. 2+ current in rabbit ventricular myocytes. Eur J Pharmacol. 1999;376:189-201.
87. Karle CA, Kreye VAW, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001;41:361-370.
88. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001:933-970.
89. Wu L, Song Y, Shyrock JC, Li Y, Antzelevitch C, Belardinelli L. Ranolazine attenuates the prolongation of ventricular monophasic action potential and suppresses ventricular tachycardia caused by sea anemone toxin ATX-II in guinea pig isolated myocytes [abstract]. PACE. 2003;26:1023.
90. Williams CD, Kovacs RJ, Sheth S, Galley C. High incidence of prolonged QTc in asthmatics [abstract]. J Am Coll Cardiol. 2004;43(suppl A):137A.
91. Fitzgerald PT, Young WF, Ackerman MJ. Pheochromocytoma and QT interval prolongation: a case series of 50 patients [abstract]. J Am Coll Cardiol. 2004;43(suppl A):141A.
92. McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA. 2004;291:216-221.
93. McBride BF, Kalus JS, Kluger J, et al. The electrocardiographic impact of catecholamines among patients at high risk of ventricular arrhythmogenesis receiving chronic carvedilol. J Electrocardiol. Submitted for publication.
94. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol. 1998;32:S22-S30.
95. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002;25:1919-1927.
96. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol. 2000;36:277-281.
97. Santos DJSL, Moreno AJM. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228. Biochem Pharmacol. 2001;61:155-164.
98. Lysko PG, Lysko KA, Webb CL, Feuerstein G, Mason PE, Walter MF, Mason RP. Neuroprotective activities of carvedilol and a hydroxylated derivative. Biochem Pharmacol. 1998;56:1645-1656.
99. Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine induced apoptosis in human coronary artery endothelial cells: modulation of the FAS/FAS ligand and caspase-3 pathway. Cardiovasc Res. 2000;45:788-794.
100. De Mey C, Breithaupt-Grogler K, Schloos J, Nuegebauer G, Palm D, Belz GG. Dose-effect and pharmacokinetic pharmacodynamic relationships of the β-1 adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther. 1994;55:329-337.
101. Metoprolol pharmacokinetics. Accessed April 17, 2004, at http://micromedex.uchc.edu/mdxcgi/display.exe?CTL=E:mdxmdxcgimegat. sys&SET=1C424EBD0DF6F00&SYS=1&T=356&D=275
102. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26:335-346.
103. Coreg (Carvedilol) [package insert]. Philadelphia: Glaxo Smith Kline; 2002.
104. Lopressor (Metoprolol Tartrate) [package insert]. Suffern, NY: Novartis Pharmaceuticals; 2004.
105. Toprol XL (Metoprolol Succinate) [package insert]. Wilmington, Del: Astra Zeneca Pharmaceuticals, 2002.
106. Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, Powell JR. Clinical pharmacology of carvedilol in normal volunteers. Clin Phar Ther. 1987;41:31-44.
107. Lucker P, Moore G, Wieselgren I, Olofsson B, Bergstrand R. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharm. 1990;30:S17-S20.
108. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 1988;33:S9-S14.
109. Maack C, Elter T, Nickenig G, et al. Prospective crossover comparison of carvedilol and metoprolol in patients chronic heart failure. J Am Coll Cardiol. 2001;38:939-46.